Boundless Bio, Inc. (Nasdaq: BOLD) completed its initial public offering on March 28, 2024, raising $100 million by selling 6.25 million shares at $16.00 per share.
The San Diego-based precision oncology company develops targeted therapies for extrachromosomal DNA (ecDNA) in previously intractable cancers.
No comments:
Post a Comment